Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial.

DRSS improvement Rates of at least 2-step DRSS improvement were largely consistent across treatment arms and between the YOSEMITE Japan subgroup and the pooled YOSEMITE/RHINE cohort at weeks 52 and 96, although there was a numerical trend for higher proportions in the faricimab arms versus the aflibercept arm in the YOSEMITE Japan subgroup (Fig. 5 ).

also in 426 other papers